CIRIUM
5.10.2022 09:01:49 CEST | Business Wire | Press release
Vueling, an airline which forms part of IAG (International Airlines Group), has signed a landmark deal with Cirium, the aviation analytics company, to improve airline operational efficiencies through the Cirium Sky managed data warehouse and analytics solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005079/en/
Vueling and Cirium sign a deal for Cirium Sky, to dramatically improve airline operational performance (Photo: Business Wire)
The multi-year deal provides Vueling, with access to Cirium’s new data aviation warehouse and analytics capability.
This partnership will allow the airline to gain a unique insight from over 25 operational factors, and ultimately provide a best-in-traveller experience.
Cirium Sky will enable more effective flight planning, especially around disruption, to minimize delays for its customers.
Jeremy Bowen, Cirium CEO, said: “Our aviation data warehouse, Cirium Sky, is critical in supporting Vueling’s digital transformation initiatives and will enable the airline to improve flight operations, reduce travel delays and set the stage for operational excellence.”
Vueling is viewed by Cirium as the agile and innovative leader in IAG thanks to the implementation of several initiatives, including Vueling Transform, to unlock its full potential through digitization and low-cost leadership.
Oliver Iffert, Vueling Chief Operations Officer , said: “Coming out of the pandemic, Vueling is emerging even more efficient and competitive as we prioritize actionable insights backed by a wealth of data and context.”
“Data is key to assessing our operations and identifying ways to provide a passenger experience that stands out.”
“Using Cirium Sky, Vueling can plan flights more effectively and analyze flight delays based on accurate data. We will, as a result, drive a reduction in delays and minimize disruptions.”
The move to Cirium Sky transitions Vueling from using multiple data providers and data held in siloed systems to a single source of aviation data and analytics.
This strategic data and analytics partnership provides the airline with access to the industry’s largest data warehouse, which has a 360-degree view of flights, as well as prescriptive and predictive analytics to anticipate future operational challenges.
Added Bowen: “Improving operations is not only key for the traveller experience but also for tackling the liquidity issues and capacity recovery that airlines are facing in the wake of COVID-19.“
“By democratizing data and enabling smarter and faster decision making, airlines would see huge savings. We are delighted to partner with Vueling and drive value for their business.”
Cirium Sky is purpose-built to enable airlines, airports, financial institutions, aircraft manufacturers, and travel distributors to unlock the value in aviation data.
Find out more about Cirium Sky.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com
About Vueling
Vueling, a company which forms part of IAG, is key in connectivity in Spain, the largest domestic market in Europe. For this winter 2022, the company has a network of more than 240 short and medium-haul routes in Europe, North Africa and the Middle East, which are operated with a fleet of Airbus A319, A320, A320neo and A321 models. In 2021, Vueling has won the World Airline Awards as the "Best Low Cost Airline in Europe".
As part of IAG, Vueling shares the vision of leading the field of sustainability within the global airline industry. That is why the company develops all its actions within the framework of the "Flightpath Net Zero" program, through which the goal of achieving net zero CO2 emissions in 2050 has been established.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom